J INTS BIO and MD Anderson Partner to Develop Brain Tumor Treatment 'JIN-001'

SEOUL, South Korea, Nov. 25, 2024 - J INTS BIO has revealed research findings on their innovative brain tumor treatment, 'JIN-001,' at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting in Texas, USA. This groundbreaking therapy was developed in collaboration with the MD Anderson Cancer Center, a world-famous cancer research institution. The partnership between J INTS BIO and MD Anderson began in 2021, focusing on advancing novel cancer treatments.

'JIN-001' is designed to target glioblastoma (GBM) cells, significantly improving the effectiveness of both radiation therapy and chemotherapy. As a selective inhibitor of Heat Shock Protein 90 (HSP90), the main advantage of JIN-001 is its ability to cross the blood-brain barrier (BBB). The BBB, while protecting the brain, often prevents therapeutic agents from accessing brain tissues. JIN-001 solves this issue by directly attacking brain tumors, overcoming the low permeability challenges faced by current drugs.

The study presented at the SNO meeting showed that JIN-001 yielded promising results when used in conjunction with standard treatments like Radiation Therapy and Temozolomide. These findings indicated that JIN-001 effectively suppresses tumor cell growth and induces apoptosis, or programmed cell death.

Looking ahead, J INTS BIO plans to accelerate preclinical trials for JIN-001, driven by the encouraging study results. The company intends to integrate CRISPR gene-editing technology to identify and understand the roles of specific genetic factors in treatment resistance. This approach aims to pave the way for precision medicine strategies, where CRISPR techniques allow targeted modulation of gene expression, aiding in the prediction and understanding of tumor responses.

Moreover, J INTS BIO is advancing its plans to commercialize JIN-001 through collaborations with international pharmaceutical companies. This effort is aimed at delivering faster and more effective treatments to brain tumor patients. The potential applications of JIN-001 are also being explored for a wide range of cancers beyond brain tumors, bringing new hope to cancer patients worldwide.

JIN-001 is a groundbreaking innovation that addresses the limitations of existing therapies, offering new treatment opportunities. It holds the promise of improved survival rates and quality of life for brain tumor patients, representing a significant advancement in cancer treatment.